Malignant melanoma stage IV

14 trials 3 recruiting MedDRA PT
14 Registered trials
3 Recruiting
9 Unique sponsors
10 Unique IMPs
9 Commercial trials
Drug classes (ATC)
— ATC code not specified 7
L Oncology (ATC L) 7
Mechanism of action (INN-stem analysis)
Unknown / small molecule 5 substances
Checkpoint inhibitor (PD-1) 2 substances
Checkpoint inhibitor (CTLA-4) 1 substance
Monoclonal antibody (immune) 1 substance
RAF/BRAF inhibitor 1 substance
Phase III: 2 Phase II: 5 Phase I: 4 Phase I (Other): 1 Phase I (First in Human): 1 Other: 1

Filter these 14 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 14 trials

Phase III

2 trials
  • Bristol Myers Squibb International Corporation Commercial
    NIVOLUMAB; NIVOLUMAB, RELATLIMAB
    2023-507688-20-00 13 countries 2021 n=601
    Ended
  • Pfizer Inc. Commercial
    PEMBROLIZUMAB
    2024-512038-13-00 11 countries 2021 n=161
    Ended

Phase II

5 trials
  • BioNTech SE Commercial
    CEMIPLIMAB; GINDAMERAN, VIBOSAMERAN, ENOMIMERAN, ONTASAMERAN
    2023-509513-36-00 4 countries 2021 n=157
    Ended
  • Genentech Inc. Commercial
    AUTOGENE CEVUMERAN; PEMBROLIZUMAB
    2023-507389-15-00 2 countries 2020 n=60
    Ended
  • Incyte Corp. Commercial
    INCB099280
    2022-502716-37-00 3 countries 2023 n=70
    Ended
  • Pfizer Inc. Commercial
    IMP not specified
    2023-509471-17-00 5 countries 2023 n=119
    Ended
  • UZ Brussel Academic
    REGORAFENIB
    2024-514087-11-02 1 country 2022 n=87
    Recruiting

Phase I

4 trials
  • Herlev Hospital Academic
    IMP not specified
    2023-509665-20-00 1 country 2024 n=10
    Recruiting
  • Herlev Hospital Academic
    IMP not specified
    2023-510417-25-00 1 country n=10
    Not authorised
  • Herlev Hospital Academic
    IMP not specified
    2023-510417-25-01 1 country 2024 n=10
    Recruiting
  • Incyte Corp. Academic
    IMP not specified
    2023-504400-29-00 1 country 2022 n=9
    Ended

Phase I (Other)

1 trial
  • Incyte Corp. Commercial
    INCB099280; IPILIMUMAB
    2023-503243-34-00 3 countries n=23
    Ended

Phase I (First in Human)

1 trial
  • Achilles Therapeutics UK Limited Commercial
    ATL001; NIVOLUMAB
    2024-513062-19-00 1 country 2022 n=8
    Ended

Other

1 trial
  • Amgen Inc. Commercial
    IMP not specified
    2022-502620-49-00 8 countries 2023 n=156
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Incyte Corp. Commercial 3 Phase I (Other), Phase II, Phase I 0
Herlev Hospital Academic 3 Phase I 2
Pfizer Inc. Commercial 2 Phase II, Phase III 0
Amgen Inc. Commercial 1 Other 0
BioNTech SE Commercial 1 Phase II 0
Genentech Inc. Commercial 1 Phase II 0
Bristol Myers Squibb International Corporation Commercial 1 Phase III 0
Achilles Therapeutics UK Limited Commercial 1 Phase I (First in Human) 0
UZ Brussel Academic 1 Phase II 1
New trials by year
2020
1
2021
3
2022
3
2023
3
2024
2
← All indication landscapes